Glenmede Trust’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
Other funds holding KYMR
BBA
Glenmede Trust's KYMR Position: Q3 2026 in Review
Glenmede Trust reduced its Kymera Therapeutics (KYMR) stake by 43% in Q3 2026, selling an estimated $361K and leaving 4,241 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #1190.
Glenmede Trust first reported a position in KYMR in Q2 2021 and has held it in 5 quarters since. The position peaked at $848K in Q2 2026. 301 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.
- Glenmede Trust held 4,241 shares of Kymera Therapeutics worth $240K as of Q3 2026.
- Glenmede Trust sold 3,153 Kymera Therapeutics shares in Q3 2026, an estimated $361K.
- Kymera Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q3 2026, its #1190 holding.
- Glenmede Trust first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 5 quarters since.
- Glenmede Trust's Kymera Therapeutics position peaked at $848K in Q2 2026.
- 301 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.
Based on Glenmede Trust's 13F filing for Q3 2026, filed 16 Nov 2026.